Medical Cannabis in Older Adults: Promising Interest, Thin Evidence

A 2019 narrative review published in Drugs & Aging finds that efficacy data for medical cannabis in adults aged 60 and older remain scanty, that safety concerns in this population are substantial and pharmacologically specific, and that the gap between patient demand and clinical evidence demands careful, individualized decision-making rather than broad endorsement or blanket prohibition.

Why This Matters

Cannabis use among older adults is rising sharply, driven by expanding legalization, media promotion, and unmet needs in chronic pain and symptom management. Clinicians treating patients over 60 are fielding questions about medical cannabis with increasing frequency, yet the evidence base they need to answer responsibly is almost entirely absent for this age group. Age-related changes in drug metabolism, polypharmacy prevalence, and vulnerability to falls and cognitive impairment make older adults a population where the risk-benefit calculation is genuinely different from that in younger adults, and where clinical guidance is urgently needed.

Clinical Summary

The endocannabinoid system modulates pain perception, sleep, appetite, mood, and immune function, providing a plausible biological basis for therapeutic cannabinoid effects across multiple symptom domains. This narrative review by van den Elsen and colleagues, published in Drugs & Aging in 2019, synthesizes pharmacological background, clinical evidence, and safety considerations to assess what is actually known about medical cannabis use in adults aged 60 and older. The review integrates data on THC, CBD, and pharmaceutical cannabinoid preparations across indications including chronic pain, cancer-related symptoms, sleep disturbance, mood disorders, and neurological conditions.

The central finding is sobering: nearly all primary studies of cannabinoid efficacy enrolled adults younger than 60, meaning direct extrapolation to older patients is scientifically uncertain. The review documents that older adults face disproportionate safety risks from cannabinoids, including impaired hepatic CYP450 metabolism leading to unpredictable drug levels, polypharmacy-driven drug interactions, cardiovascular effects, and heightened susceptibility to cognitive impairment and gait instability. Cannabis prevalence among U.S. adults over 50 rose from 5% past-month use in 2014 to 9% past-year use by 2015 to 2016, underscoring the public health urgency. The authors conclude that individualized shared decision-making is the only defensible clinical approach given the current evidence gap, and they call for dedicated clinical trials in older populations before any population-level prescribing guidance can be responsibly issued.

Dr. Caplan’s Take

This review captures a tension I see daily in practice. Older patients come in having read that cannabis might help their chronic pain, their insomnia, or their nausea, and they deserve an honest answer. The honest answer is that the biological rationale is real but the clinical evidence for their specific age group barely exists. What we do know about age-related pharmacokinetics, particularly CYP450 changes and increased sensitivity to central nervous system depressants, gives genuine reason for caution rather than reflexive enthusiasm.

In my practice, I do not dismiss these conversations and I do not wave patients away. I walk through the specific risks that apply to their situation: their medication list, their fall history, their cognitive baseline. If we proceed, it is with low doses, careful titration, close monitoring, and explicit agreement that we are working in an evidence-thin space. That is what responsible cannabinoid medicine looks like for this population right now: not blanket prohibition, not casual prescription, but structured clinical humility.

Clinical Perspective

This review sits at an early point in the research arc for geriatric cannabinoid medicine. It confirms what many clinicians suspect: that the rapid expansion of cannabis access has outpaced the generation of age-specific evidence. The pharmacokinetic reasoning the authors present, particularly around CYP450-mediated metabolism and lipophilic drug accumulation in older adults, is well grounded and clinically useful even where direct trial data are absent. However, the review does not resolve the fundamental question of whether cannabinoids offer meaningful net benefit for any specific indication in this population. Until dedicated trials are conducted, clinicians cannot make evidence-based efficacy claims to older patients, only evidence-informed risk assessments.

From a safety standpoint, clinicians should pay particular attention to CYP3A4 and CYP2C9 interactions, as both THC and CBD are metabolized through these pathways and many medications commonly prescribed to older adults (including warfarin, certain statins, and calcium channel blockers) share these routes. The additive risk of central nervous system depression when cannabinoids are combined with opioids, benzodiazepines, or sedating antihistamines deserves explicit discussion. One concrete step clinicians can implement now is incorporating a structured medication interaction review before any cannabinoid initiation in patients over 60, using the same rigor applied when adding any new psychoactive medication to a complex regimen.

Study at a Glance

Study Type

Narrative review with clinical recommendations

Population

Older adults aged 60 and above (though cited primary studies mostly enrolled adults under 60)

Intervention

THC, CBD, pharmaceutical cannabinoids, and medical cannabis preparations

Comparator

Not applicable (review article)

Primary Outcomes

Efficacy evidence and safety profile across chronic pain, sleep, cancer symptoms, mood, and neurological conditions

Sample Size

Not applicable (narrative synthesis of existing literature)

Journal

Drugs & Aging

Year

2019

DOI

10.1007/s40266-018-0616-5

Funding Source

Not reported in available text

What Kind of Evidence Is This

This is a narrative review, which occupies a relatively low position in the evidence hierarchy compared to systematic reviews or meta-analyses. It synthesizes pharmacological background, clinical trial summaries, and expert clinical judgment without a described systematic search strategy, PRISMA protocol, or quantitative evidence pooling. The most important inference constraint this imposes is that the completeness and balance of the literature coverage cannot be independently verified, meaning that studies showing null results or harm may be underrepresented in the synthesis.

How This Fits With the Broader Literature

This review is consistent with conclusions from other assessments of the geriatric cannabis evidence base, including the 2017 National Academies of Sciences report on cannabis therapeutics, which similarly noted that high-quality evidence for most indications is limited and that older adults are systematically underrepresented in cannabinoid trials. It also aligns with Abuhasira and colleagues’ 2018 prospective study of medical cannabis in patients over 65, which found symptom improvements but also a notable adverse event rate. The present review extends these observations by explicitly integrating pharmacokinetic reasoning about why older adults may respond differently to cannabinoids, though it does not add new primary data to the conversation. The fundamental gap it identifies, the near-total absence of randomized controlled trials enrolling adults over 60, remains unresolved as of publication.

Common Misreadings

The most likely overinterpretation of this review is reading its acknowledgment of biological plausibility and its pragmatic clinical framework as a form of endorsement for medical cannabis use in older adults. It is not. The authors are explicit that biological rationale and patient demand do not substitute for clinical evidence, and their recommendation for shared decision-making is offered precisely because the evidence to support stronger guidance does not exist. A related misreading would be to cite the rising prevalence data as evidence of safety or tolerability; increased use reflects cultural and legal shifts, not clinical validation.

Bottom Line

This review consolidates what is known about medical cannabis in older adults and finds that the answer is: not nearly enough. The biological rationale is real, patient interest is rising, and safety concerns specific to aging physiology are well articulated. But high-quality clinical evidence for efficacy in adults over 60 is almost entirely absent. Until dedicated trials address this gap, clinical decisions must be individualized, cautious, and transparent about the limits of current knowledge.

References

1. van den Elsen GAH, Ahmed AIA, Lammers M, et al. Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Research Reviews. 2014;14:56-64.
2. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
3. Abuhasira R, Schleider LBL, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. European Journal of Internal Medicine. 2018;49:44-50.
4. van den Elsen GAH, Tobben L, Stijnen T, et al. Medical cannabis in older adults: a narrative review. Drugs & Aging. 2019. DOI: 10.1007/s40266-018-0616-5.